cPMP Inhibitors
1 drugsAbout cPMP
Cyclic pyranopterin monophosphate (cPMP) is a molecule whose precise biological function requires further research. Its amenability to therapeutic intervention is confirmed by the existence of an approved drug.
Currently, there is no genetic evidence available linking cPMP to specific diseases, limiting understanding of its direct involvement in disease pathology. Further research is needed to elucidate the precise role of cPMP in relevant biological pathways.
cPMP is targeted by one FDA-approved drug, NULIBRY, a small molecule approved in 2021. SENTYNL THERAPS INC is the sole company with an approved drug for this target, addressing an 'Other' therapeutic area.
Top cPMP Drugs
SENTYNL THERAPS INC is the only company with an approved drug targeting cPMP.
The market is not competitive, suggesting high barriers to entry or limited commercial interest.
cPMP Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets cPMP, using small molecule modality.
The modality landscape presents an opportunity to explore alternative modalities like antibodies or peptides.
cPMP Drug Approval Timeline (2021 - 2021)
NULIBRY was the first and most recent drug approved in 2021.
The recent approval suggests a potential for further drug development, but also a risk of market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Full summary • All drugs • Genetic evidence • Trials • Timeline